Literature DB >> 2974798

Plasma atrial natriuretic peptide in states of altered thyroid function.

T Yamaji1, M Ishibashi, F Takaku, F Sato, K Kamoi.   

Abstract

To examine a possible role of atrial natriuretic peptide (ANP) in water and electrolyte disturbances associated with thyroid disorders, plasma ANP levels were studied in patients with hyper- and hypothyroidism. In 5 of the 21 hyperthyroid patients, including two patients with atrial fibrillation and two patients with mild cardiomegaly, the plasma ANP concentration was increased when compared to normal subjects. After treatment with methimazole or propylthiouracil, the plasma ANP concentration fell to normal in 4 patients, while it remained high in one patient who had persistent atrial fibrillation. No significant correlation was found between plasma ANP and the heart rate in untreated hyperthyroid patients. Plasma ANP was within the normal range in all 8 patients with hypothyroidism. During treatment with T4, the plasma ANP concentration increased in 6 of the 7 patients. Chest X-ray films and ultrasonic echocardiography demonstrated pericardial effusion in 4 of these patients before therapy. A weak but significant correlation was found between the plasma ANP and T4 concentration, and between plasma ANP and free T4 in hyper- and hypothyroid patients before and after treatment. These results indicate that abnormalities in ANP dynamics in thyroid disorders may probably be caused by hemodynamic changes resulting from a thyroid hormone excess or deficiency.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974798     DOI: 10.1507/endocrj1954.35.343

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  1 in total

1.  Atrial natriuretic peptide and cyclic guanosine monophosphate plasma concentrations in patients with thyrotoxicosis and atrial fibrillation. Effect of short-term methimazole therapy.

Authors:  S Czekalski; K Widecka; J Gozdzik; K Ciechanowski; B Krzyzanowska-Swiniarska; E Gromniak; M Gruszczynska
Journal:  J Endocrinol Invest       Date:  1994-05       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.